Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tryp Therapeutics Inc (OP: TRYPF ) N/A UNCHANGED Last Price Updated: 3:17 PM EDT, May 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Tryp Therapeutics Inc < Previous 1 2 Next > Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing April 25, 2024 Tryp Therapeutics finalizes merger with Exopharm, prepares for ASX listing with strategic shareholder benefits. Explore merger details now! Via Benzinga Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More January 12, 2024 Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD Via Benzinga Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia January 08, 2024 Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Via Benzinga Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy's Garden And More July 19, 2023 GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote Via Benzinga Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital July 13, 2023 Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital... Via Benzinga Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making June 13, 2023 Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with... Via Benzinga Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS May 24, 2023 Tryp Therapeutics, Inc. (OTCQB: TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S. Via Benzinga Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More May 01, 2023 Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued Via Benzinga Tryp Therapeutics Secures $1.6M Via Oversubscribed Private Placement April 27, 2023 Tryp Therapeutics Inc. (OTCQB: TRYPF) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high... Via Benzinga EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key' April 14, 2023 Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental... Via Benzinga Therapists At Mass General Hospital Prepared To Assist IBS Patients With Psilocybin Therapy April 04, 2023 Psychotherapists at the Massachusetts General Hospital (MGH) have undergone training by lead business Fluence toward participating in Tryp Therapeutics (OTCQB: T Via Benzinga What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry April 03, 2023 The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. Via Benzinga Psyched: NY Discusses Regulations, MDMA For PTSD Aims For Legalization, Shrooms For Eating Disorders & More January 10, 2023 Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's... Via Benzinga Treating Binge Eating Disorder With Magic Mushrooms: Phase 2 Clinical Trial Gets Thumbs Up January 05, 2023 Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. Via Benzinga Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients January 03, 2023 Psychedelics company Tryp Therapeutics Inc. Via Benzinga This Psychedelics Company Is Patenting Its Psilocin And Psilocybin Delivery Route October 04, 2022 The World Intellectual Property Organization (WIPO) has published clinical-stage biopharma Tryp Therapeutics Inc. (OTCQB: TRYPF)’s international patent application for the intravenous (IV)... Via Benzinga Is Psilocybin Therapy A Potential Treatment For Fibromyalgia & Binge Eating Disorder? September 26, 2022 Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding... Via Benzinga Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma September 14, 2022 Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options Via Benzinga Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill June 15, 2022 Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. Via Benzinga Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far June 09, 2022 Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases. Via Benzinga These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry June 02, 2022 In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... Via Benzinga Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward May 02, 2022 The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions. Via Benzinga Could Magic Mushrooms Be A Solution For Overeating? New Clinical Trial Intends To Find Out April 28, 2022 Psilocybin, the active ingredient in “magic mushrooms,” could be part of the solution for people struggling with binge eating disorder, a condition characterized by recurring episodes of eating large... Via Benzinga FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics December 23, 2021 Tryp Therapeutics (CSE:TRYP) (OTCQB: Via Benzinga Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval November 08, 2021 Detroit Decriminalizes Psychedelics Via Benzinga Exposures Product Safety Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation October 18, 2021 The Week In Psychedelics Via Benzinga There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are October 13, 2021 Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... Via Benzinga Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold August 30, 2021 Contents Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021 August 26, 2021 Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE: Via Benzinga Psyched: Cybin And Field Trip Head To Wall Street, AOC Pushes For Federal Psychedelics Research, Off-Label Ketamine Covered By Insurance In Canada July 26, 2021 Cybin Inc. (NEO: CYBN) (OTCQB: Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.